MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13063-025-09226-6

Медицинская библиотека · Trials · 2025

Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial.

Blomberg Bjørn, Myklebust Nikolai Norevik, Oppegaard Oddvar, Tøndel Camilla, Cox Rebecca Jane, Iversen Arild, Lehmann Marianne Emblem, Sandvig Axel, Dahl Tuva Børresdatter, Valderhaug Vibeke Devold, Szodoray Peter, Wilhelmsen Maja, Kirsebom Bjørn Eivind, Glambek Marte, Kaarbøe Oddvar, Aukrust Pål, Lie Rolv Terje, Langeland Nina

СтатьяПротокол клинического исследованияПеревод пока не подготовлен

Аннотация

BACKGROUND

The high prevalence of long-term persisting symptoms after COVID-19 (coronavirus disease 2019), termed long COVID or post-COVID-19 condition, even among those with mild initial disease, may have a large public health impact. Apart from avoiding infection, there is no proven prevention or treatment for long COVID. We will perform a randomized placebo-controlled clinical trial to assess whether treatment with the novel antiviral, nirmatrelvir and ritonavir (Paxlovid®) for acute COVID-19 can prevent the development of long COVID.

METHODS

This is a randomized double-blinded placebo-controlled trial that aims to recruit 2000 nonpregnant persons aged 18 to 64 years with acute COVID-19 with positive PCR and/or antigen test and symptom duration of not more than 5 days. Participants will be randomized 1:1 to a 5-day course of Paxlovid (two tablets 150-mg nirmatrelvir and one tablet 100-mg ritonavir twice daily) or a 5-day course of placebo (similar number of tablets of equal appearance). The primary endpoint will be persistent symptoms compatible with long COVID, assessed as the prevalence of a dichotomous variable corresponding to the presence (1) or absence (0) of one or more of the following symptoms: (i) fatigue, (ii) dyspnea, and (iii) cognitive symptoms (memory and/or concentration problems). The primary outcome will be evaluated at 3-month follow-up and then re-evaluated at 6, 12, and 24 months.

DISCUSSION: As more than 750 million people with confirmed COVID-19 have survived globally, the potential burden of long COVID on societies is formidable. If a simple 5-day oral treatment course with nirmatrelvir/ritonavir is shown to prevent long COVID, it would be a highly attractive intervention at an individual level and a mitigation of its public health consequences.

TRIAL REGISTRATION: ClinicalTrials.gov NCT05852873. Registered on May 2023.

Для цитирования: Blomberg Bjørn, Myklebust Nikolai Norevik, Oppegaard Oddvar, Tøndel Camilla, Cox Rebecca Jane, Iversen Arild, Lehmann Marianne Emblem, Sandvig Axel, Dahl Tuva Børresdatter, Valderhaug Vibeke Devold, Szodoray Peter, Wilhelmsen Maja, Kirsebom Bjørn Eivind, Glambek Marte, Kaarbøe Oddvar, Aukrust Pål, Lie Rolv Terje, Langeland Nina. Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial.. Trials. 2025. DOI: 10.1186/s13063-025-09226-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.